# Eltrombopag Plus Telitacicept vs. Eltrombopag Alone for Steroid-refractory/Relapsed ITP

> **NCT07687134** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 40 (estimated)

## Conditions studied

- Immune Thrombocytopenia

## Interventions

- **DRUG:** Eltrombopag

## Key facts

- **NCT ID:** NCT07687134
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-10
- **Primary completion:** 2026-07-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-07-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07687134

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07687134, "Eltrombopag Plus Telitacicept vs. Eltrombopag Alone for Steroid-refractory/Relapsed ITP". Retrieved via MORVS 2026-10-22 from https://api.morvs.ai/clinical/NCT07687134. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*